Compare Iron Mountain Inc (IRM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iron Mountain Inc vs Novartis AG — how do they compare? Iron Mountain Inc trades at $114.09 (market cap $34.46B), while Novartis AG trades at $143.2 (market cap $268.57B). The key difference: Novartis AG is far larger — about 7.8× Iron Mountain Inc's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Iron Mountain Inc for 80 Days and Novartis AG for 82 Days on average.
| IRM | NVS | |
|---|---|---|
Market Cap | $34.46B | $268.57B |
Volume | 1,379,608 | 1,532,573 |
Sector | Real Estate | Health |
52-Week High | $133.06 | $168.62 |
52-Week Low | $78.86 | $121.80 |
Typical Hold Time | 80 Days | 82 Days |
Enterprise Value | $53.87B | $309.89B |
Dividend Yield | 2.99% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $115.73, down 0.66% on the day, with a bullish technical signal and strong institutional interest. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, climbing from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed. Recent news highlights expansion in data centers and digital partnerships, including a 300MW pipeline and AI collaborations.
The outlook is supported by analyst consensus with a $142.75 price target (66.7% buy ratings), but high debt levels and elevated P/E of 82.09 pose risks. Earnings growth from digital initiatives is the key catalyst, while leverage and margin pressure require monitoring for sustained shareholder value.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
